Success all round for Cancer Research UK supported spinouts at the OBN annual awards

2018-10-19 00:00:00

The OBN Annual Awards proved a night of big success for Cancer Research UK, with the 10th anniversary celebrating innovation and achievement in the Life Sciences Industry. 

2018 Outstanding Achievement Award - GammaDelta Therapeutics

GammaDelta Therapeutics, formed in 2016 by Abingworth with support from Cancer Research UK's Commercial Partnerships Team (previously known as CRT), received the 2018 Outstanding Achievement Award. GammaDelta Therapeutics was founded on research part funded by Cancer Research UK, led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, into tissue resident gamma delta T cells. Gamma delta T cells are a unique class of lymphocytes that contribute to many immunological responses and diseases, and GammaDelta aim to utilise this knowledge to develop improved immunotherapies for cancer and other diseases.

Best Start-up Biotech Company Award - IGEM Therapeutic

Further success emerged with an additional Cancer Research-associated spinout, IGEM Therapeutics, winning the Best Start-up Biotech Company award. IGEM Therapeutics is an Immuno-Oncology Biotech that promotes development of IgE antibody drugs to fight cancer.

Notes to editors